LONDON (Reuters) – London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is on hold while talks with the UK government continue.
“We’re still in discussions with the government to figure out what type of incentives there may be. We don’t have anything new to report at this time,” AstraZeneca’s Chief Financial Officer Aradhana Sarin said during a media briefing after the company reported third-quarter results.
When asked if the investment was on hold while these talks continue, Sarin replied: “That’s correct.”
($1 = 0.7802 pounds)
(Reporting by Maggie Fick in London and Chandini Monnappa in Bengaluru; Editing by Jan Harvey)
